Switzerland approves a vaccine targeting two Covid variants
The Swiss medicines agency Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to protect against two different strains of the virus.
This content was posted on August 29, 2022 – 12:54 PM
swissinfo.ch/mga
The Spikevax Bivalent Original/Omicron is intended for administration in two 0.5 ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of another mRNA targeting the Omicron variant (BA.1 and BA.4/5).
On Monday, said Swissmedicexternal link that the dual vaccine in experiments achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side effects”.
These side effects may include irritation, redness, or swelling at the injection site, tiredness, headache, chills, or nausea.
According to Swissmedic, the Commission of Experts for Human Medicinal Products has also given the new vaccine a separate seal of approval.
In accordance with JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative